Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 29;15(1):54.
doi: 10.1186/s13065-021-00780-z.

Design, synthesis, and biological evaluation of symmetrical azine derivatives as novel tyrosinase inhibitors

Affiliations

Design, synthesis, and biological evaluation of symmetrical azine derivatives as novel tyrosinase inhibitors

Somaye Karimian et al. BMC Chem. .

Abstract

A series of symmetrical azine derivatives containing different substituted benzyl moieties were designed, synthesized, and evaluated for their inhibitory activity against tyrosinase. The results showed that compounds 3e, 3f, 3h, 3i, 3j, and 3k possess effective tyrosinase inhibition with IC50 values ranging from 7.30 μM to 62.60 μM. Particularly, compounds 3f displayed around three-fold improvement in the potency (IC50 = 7.30 ± 1.15 μM) compared to that of kojic acid (IC50 = 20.24 ± 2.28 μM) as the positive control. Kinetic study of compound 3f confirmed uncompetitive inhibitory activity towards tyrosinase indicating that it can bind to enzyme-substrate complex. Next, molecular docking analysis was performed to study the interactions and binding mode of the most potent compound 3f in the tyrosinase active site. Besides, the cytotoxicity of 3f, as well as its potency to reduce the melanin content were also measured on invasive melanoma B16F10 cell line. Also, 3f exhibited above 82% cell viability in the A375 cell line at 10 µM. Consequently, compounds 3f could be introduced as a potent tyrosinase inhibitor that might be a promising candidate in the cosmetics, medicine, and food industry.

Keywords: Azine derivatives; Melanin; Molecular docking; Tyrosinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Chemical structures of some tyrosinase inhibitors from natural or synthetic sources
Fig. 2
Fig. 2
Molecular hybridization and fragment-based approach for designing of bis-aryl hydrazine derivatives as tyrosinase inhibitors
Scheme 1
Scheme 1
The synthetic route for the synthesis of bis aryl hydrazine derivatives (3ak)
Fig. 3
Fig. 3
Lineweaver–Burk plot of mushroom tyrosinase enzyme inhibition by different concentrations of 3f in the presence of L-DOPA as a substrate. The reciprocal tyrosinase inhibitory activity was plotted against the reciprocal substrate concentration (double reciprocal plot, n = 3). Km is the Michaelis–Menten constant and Vmax is the maximum reaction velocity
Fig. 4
Fig. 4
The binding orientation (a) and interactions (b) of compound 3f into the tyrosinase enzyme. Ligand 3f is displayed as cyan sticks, while the core residues are shown as green sticks. Hydrogen bonding, electrostatic, Pi–Pi, and alkyl-Pi interactions are displayed as green, orange, pink and light pink, respectively
Fig. 5
Fig. 5
Effect of compound 3f on melanin content in B16F10 melanoma cells

References

    1. Zhu Y-J, Qiu L, Zhou J-J, Guo H-Y, Hu Y-H, Li Z-C, Wang Q, Chen Q-X, Liu B. Inhibitory effects of hinokitiol on tyrosinase activity and melanin biosynthesis and its antimicrobial activities. J Enzyme Inhib Med Chem. 2010;25(6):798–803. doi: 10.3109/14756360903476398. - DOI - PubMed
    1. Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem Photobiol. 2008;84(3):539–549. doi: 10.1111/j.1751-1097.2007.00226.x. - DOI - PMC - PubMed
    1. Lerner AB, Fitzpatrick TB. Treatment of melanin hyperpigmentation. J Am Med Assoc. 1953;152(7):577–582. doi: 10.1001/jama.1953.03690070011004. - DOI - PubMed
    1. Kim YJ, Kang KS, Yokozawa T. The anti-melanogenic effect of pycnogenol by its anti-oxidative actions. Food Chem Toxicol. 2008;46(7):2466–2471. doi: 10.1016/j.fct.2008.04.002. - DOI - PubMed
    1. Bose A, Petsko GA, Eliezer D. Parkinson’s disease and melanoma: co-occurrence and mechanisms. J Parkinsons Dis. 2018;8(3):385–398. doi: 10.3233/JPD-171263. - DOI - PMC - PubMed

LinkOut - more resources